Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Net loss from continuing operations was $ (20.5) million and $ (38.9) million for the three and nine months ended September 30, 2024, respectively, compared to $ (8.2) million and $ (45.3) million for ...